Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 323

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 323
---
 operations(21,906)(11,292)(10,614)Other income:Interest income3,667 2,566 1,101 Other income171 174 (3)Total other income:3,838 2,740 1,098 Net loss$(18,068)$(8,552)$(9,516)

 Research and Development Expenses

The following table summarizes our research and development expenses (in thousands):

Three Months Ended June 30,Change20252024Direct research and development expenses by program:NBD1 and combination development programs(1)$8,815 $3,403 $5,412 Complementary modulator programs1,430 1,475 (45)Unallocated research and development expenses:Personnel-related (including stock-based compensation)3,577 2,217 1,360 Other R&D related costs931 523 408 Facility, lab and depreciation630 615 15 Total research and development expenses$15,383 $8,233 $7,150 

(1)NBD1 and combination development program costs include NBD1 stabilizer activities and development of our proprietary combination therapy. Complementary modulator program costs include manufacturing expenses for the complementary modulators.

Research and development expenses increased by $7.2 million to $15.4 million for the three months ended June 30, 2025, from $8.2 million for the three months ended June 30, 2024. The increase in research and development expenses was primarily due to:

•direct research and development expenses increased by $5.4 million primarily due to an increase in clinical programs and combination development activities; and

•unallocated research and development expenses increased by $1.8 million primarily due to a $1.4 million increase in personnel-related expenses including stock-based compensation, driven by an increase in the size of our workforce to support our clinical pipeline. 

20

General and Administrative Expenses

The following table summarizes our general and administrative expenses (in thousands):

Three Months Ended June 30,Change20252024Personnel-related (including stock-based compensation)$4,174 $1,842 $2,332 Professional services & fees1,871 827 1,044 Facility and depreciation478 390 88 Total general and administrative expenses$6,523 $3,059 $3,464 

General and administrative expenses increased by $3.5 million to